secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001493152-26-002883
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology updates ateganosine program, targeting early commercial approval in NSCLC
--------------------------------------------------------------------------------

- Ateganosine obtained FDA Fast Track designation for NSCLC in 2025; company expects potential Accelerated Approval and Priority Review.
- Initiated THIO-104 Phase 3 trial in 3L NSCLC; Phase 2 Part C expansion underway in Asia and Europe.
- Awarded $2.3M NIH grant for Phase 2 trial; raised ~$17.6M in 2025 capital raises with board participation.
- Targeted 2026 milestones: interim efficacy data from Phase 3, completion of Phase 2 Part C, and start of Phase 1 for second-generation molecules.
- Company claims ateganosine is the only telomere-targeting anticancer agent in clinical development globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315226002883/0001493152-26-002883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315226002883/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-002883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer